GeneHub is redefining Real World Data (RWD) in drug development by placing patients at the center. Today, biopharma depends on RWD — especially genetic data — to develop and approve treatments for rare and complex diseases. Yet this data is typically sourced through intermediaries, de-identified, fragmented, and locked into one-time use due to consent constraints. The result: trials fail, costs spiral, and personalised medicine is held back.

GeneHub changes that. We give patients full control of their data — from health records and symptom tracking to genomics and surveys — keeping it linked, secure, and governed by dynamic consent. Instead of handing over raw data, patients unify it in a single, secure hub. Biopharma gains real-time, regulatory-grade insights while maintaining ethical distance — no intermediaries, no privacy headaches.

Our longitudinal, reusable RWD model not only unlocks early patient stratification and protocol optimisation but also boosts regulatory confidence through verifiability and transparency. GeneHub shortens timelines, saves millions, and brings life-saving treatments to patients faster.

GeneHub is powering the future of personalised medicine — ethical, efficient, and patient-driven.